|
Market Closed -
Euronext Paris
11:55:00 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 2.316 EUR | -2.44% |
|
-5.00% | -31.48% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Conducting of Research and Development of Epicutaneous Immunotherapy Products | 5.71M | 4.84M | 15.73M | 4.15M | 5.64M | |||||
Total Assets | 147M | 247M | 183M | 65.66M | 234M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | -381K | 70K | 7K | 55K | 491K | |||||
CAPEX | -918K | -754K | -677K | -2.34M | -532K | |||||
EBT | -98.19M | -96.2M | -72.72M | -114M | -146M | |||||
D&A | 8.38M | 13.16M | -14M | -925K | 3.19M | |||||
Operating Income | -98.61M | -96.63M | -76.43M | -117M | -147M | |||||
Net Income | -97.81M | -96.27M | -72.73M | -114M | -147M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
France | 5.71M | 4.84M | 15.73M | 4.15M | 5.64M | |||||
Total Assets | 147M | 247M | 183M | 65.66M | 234M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | -381K | 70K | 7K | 55K | 491K | |||||
D&A | 8.38M | 13.16M | -14M | -925K | 3.19M | |||||
CAPEX | -918K | -754K | -677K | -2.34M | -532K | |||||
Net Income | -97.81M | -96.27M | -72.73M | -114M | -147M | |||||
EBT | -98.19M | -96.2M | -72.72M | -114M | -146M | |||||
Operating Income | -98.61M | -96.63M | -76.43M | -117M | -147M |
- Stock Market
- Stocks
- DBV Stock
- Financials DBV Technologies
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
